louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05621681: This Prospective Study Has 2 Objectives: First, to Assess the Post-obturation Pain Utilizing Bioceramic Sealer and One Cone Technique. Second, to Compare the Intensity of Post-obturation Pain Following Unintentional Sealer Extrusion
Official title: Postoperative Pain Assessment Following Unintentional Bioceramic Sealer Extrusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Postoperative
Endodontic Overfill
Keywords: Sealer extrusion
Postoperative pain
Lead sponsor: Qassim University
Sponsor class: OTHER
First posted: 2022-11-18
Enrollment: 145
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Primary dental care

Brief summary: Root canal treatment is essential step to eliminate pain and preserve tooth structures. However, errors could happen unintentionally such as ledge, perforation and sealer extrusion.

Pain through an endodontic treatment is one of the elements that most of the patients seek treatment to be relived.

One the current systemic review analyzed the pain after root canal treatment could be up to half the patients.

The purpose of this study is to evaluate and record the postoperative pain among patients who are undergoing root canal treatment.


Eligibility criteria: "Inclusion Criteria":

* Primary root canal
* Asymptomatic tooth with or without apical radiolucency
* Patient older than 18 and younger than 70
* American Society of Anesthesiology (ASA) Class I or II

"Exclusion Criteria":

* Patient with preoperative pain
* Periodontal probing more than 5mm
* When patency could not be achieved
* pregnant patient.,
* patients who could not properly follow the instructions for filling the visual analog card (VAS) were excluded.
* Previously treated or initiated

Primary outcomes:
measure: Each patient was given visual assessment scale to analyze the postoperative pain and assessing the change in different time intervals (6 hours,24 hours,2 days,3days and 4 days)
timeFrame: Five times intervals were recorded at the following: 6 hours following the treatment,1 day,2days,3days and 4 days
Secondary outcomes:
Other outcomes:
Locations:
city: Buraidah
country: Saudi Arabia
facility: Abdulaziz Abdulmunim
state: Qassim
Study officials:
References:
Clinical trial NCT05658081: Comparison of Two Stapled Antimesenteric Anastomosis for CD: a Randomized Control Trial Study
Official title: Stapled Antimesenteric Functional End-to-end Anastomosis (Kono-S) Versus Stapled Antimesenteric Isoperistaltic Side-to-side Anastomosis for the Postoperative Recurrence of Crohn's Disease: a Randomized Control Trial Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Crohn Disease
Recurrence
Lead sponsor: Jinling Hospital, China
Sponsor class: OTHER
First posted: 2022-12-20
Enrollment: 236
Sex: ALL
Minimum age (years): 16
Maximum age (years): 60
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The postoperative recurrence of Crohn's diseases (CD) remains high. Stapled anti-mesenteric functional end-to-end anastomosis was safe for CD patients. Its impact on the postoperative recurrence of CD was unknown. Whether it is superior than the conventional anastomosis (stapled antimesenteric isoperistaltic side-to-side anastomosis) needs explored. The trial aims to compare the different impacts of the two antimesenteric anastomosis configurations on the anastomotic recurrence following bowel resection.


Eligibility criteria: Inclusion Criteria:

* patients with Crohn's disease needing bowel resection and anastomosis;
* ileocolic anastomosis；
* written consent acquired

Exclusion Criteria:

* patients underwent enterostomy;
* small bowel anastomosis;
* anticipating other trial.

Primary outcomes:
measure: the endoscopic recurrence rate at 1 year after surgery
timeFrame: at 1 year after surgery(6-18month)
Secondary outcomes:
measure: the clinical recurrence rate at 1 and 5 year after surgery
timeFrame: 1 and 5 year after surgery
measure: the surgical recurrence rate at 1 and 5 year after surgery
timeFrame: 1 and 5 year after surgery
measure: the endoscopic recurrence rate at 1 year after surgery
timeFrame: 1 and 5 year after surgery
measure: quality of life for CD patients inflammatory bowel disease questionnaire(IBDQ)
timeFrame: 1 and 5 year after surgery
measure: quality of life for CD patients Short Form 12
timeFrame: 1 and 5 year after surgery
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Department of General Surgery, Jinling hosptal,Medical School of Nanjing University
state: Jiangsu
Study officials:
affiliation: Jinling Hospital，Nanjing， China
name: Yi Li, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01392781: Markers and Calculation of Cardiovascular Risk in the Distinct Phenotypes of Polycystic Ovary Syndrome
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Polycystic Ovary Syndrome
Keywords: PCOS
hsC-RP
Lp-PLA2
cardiovascular risk
Lead sponsor: Aristotle University Of Thessaloniki
Sponsor class: OTHER
First posted: 2011-07-13
Enrollment: 300
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Outpatient women with PCOS (normalweight, overweight plus obese) Healthy volunteers controls (normalweight, overweight plus obese)

Brief summary: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder and cause of anovulatory infertility among reproductive aged women. According to the revised criteria of 2003, four distinct phenotypes of PCOS can be diagnosed. However, there are emerging evidence supporting the existence of different levels of cardiometabolic risk between the four phenotypic groups of the syndrome. The purpose of this study is to determine the cardiovascular risk of i) normoweight and ii)overweight plus obese women of every one of the four phenotypes of the syndrome as well as the levels of low inflammation serum markers and the possible correlations of the between the outcomes.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of PCOS (criteria 2003)
* Healthy controls

Exclusion Criteria:

* any condition mimicking PCOS
* any systematic disease

Primary outcomes:
measure: high sensitivity C-Reactive Protein (hsC-RP) levels and differences between the phenotypes
timeFrame: 1 hour
measure: Lipoprotein-associated phospholipase2 (Lp-PLA2) levels and differences between the phenotypes
timeFrame: 1 hour
measure: Cardiovascular Risk Assessment and differences between the phenotypes
timeFrame: 1 hour
Secondary outcomes:
Other outcomes:
Locations:
city: Thessaloniki
country: Greece
facility: Second Department of Obstetrics and Gynecology, Third Department of Cardiology, Second Propedeutic Department of Internal Medicine, Aristotle University
Study officials:
References:
citation: Daskalopoulos G, Karkanaki A, Piouka A, Prapas N, Panidis D, Gkeleris P, Athyros VG. Excess Metabolic and Cardiovascular Risk is not Manifested in all Phenotypes of Polycystic Ovary Syndrome: Implications for Diagnosis and Treatment. Curr Vasc Pharmacol. 2015;13(6):788-800. doi: 10.2174/1567201812666150120163025.
Clinical trial NCT01317381: ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill
Official title: ICG- Livertest Versus New Biomarkers as Prognostic Markers in Critically Ill
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Critically Ill Patients
Lead sponsor: University of Zurich
Sponsor class: OTHER
Collaborators: name: Intuitive Surgical
First posted: 2011-03-17
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Admitted ICU Patients

Brief summary: ICG- Leberfunktionstest versus "neue" Biomarker als prognostischer Marker bei intensivmedizischen Patienten


Eligibility criteria: Inclusion criteria: Gruppe 1:

* Intensiv-Patienten mit Verbrennungen \> 10% der Körperoberfläche
* Alter \> 18

Gruppe 2:

* Intensivpatienten nach grossen chirurgischen Eingriffen
* Alter \> 18

Gruppe 3:

* Polytraumatisierte, intensivpflichtige Patienten
* Alter \> 18

Exclusion criteria: • Alter \< 18

* Schwangerschaft
* Einschluss in eine andere Studie
* Moribunde Patienten
* Patienten, die kein Deutsch verstehen
* Jodunverträglichkeit

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Zurich
country: Switzerland
Study officials:
affiliation: UniversitaetsSpital Zuerich
name: 01 Studienregister MasterAdmins
role: STUDY_DIRECTOR
References:
Clinical trial NCT03585881: Accuracy of 3DPrinted Windowed Bracket- Positioning Guide Compared To Thermoformed Indirect Bonding Tray
Official title: Evaluation of Accuracy of 3DPrinted Windowed Bracket- Positioning Guide Compared To Thermoformed Transfer Tray For Orthodontic Indirect Bonding A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Inaccurate Transfer and Bond Failure of Conventional Indirect Bonding Tray
Accuracy of Bracket Transfer and Bond Failure Rate of Digitally Printed Transfer Tray With Windows and Conventional Thermoformed Transfer Tray
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2018-07-13
Enrollment: 132
Sex: ALL
Minimum age (years): 13
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: this study was aimed to evaluate of accuracy of 3DPrinted windowed Bracket- Positioning Guide in compare to Thermoformed Transfer Tray For Orthodontic Indirect Bonding


Eligibility criteria: Inclusion Criteria:

1. Age: above 13 years.
2. Complete set of permanent teeth including second molar.
3. No sex predilection.
4. Class I Mild to moderate crowding (4-6 mm).

Exclusion Criteria:

1. Surface enamel defect that compromise bonding
2. No or poor patient's compliance.
3. Psychological problems.
4. Pathology at the site of intervention.
5. Insufficient crown height that contradicts bonding of brackets.
6. Labial and buccal Restorations.
7. Poor oral hygiene.
8. Severely rotated teeth

Primary outcomes:
measure: accuracy of 3D printed transfer tray with windows& conventional thermoformed transfer tray
timeFrame: immediate
Secondary outcomes:
measure: chairside time
timeFrame: immediate
measure: immediate bond failure
timeFrame: immediate
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01000181: Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT
Official title: A Mechanistic, Non-randomised Study to Examine the Uptake of a Specific Radionuclide (61CuATSM) in Carotid Artery Plaque
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Carotid Atherosclerosis
Lead sponsor: King's College London
Sponsor class: OTHER
Collaborators: name: Guy's and St Thomas' NHS Foundation Trust
First posted: 2009-10-22
Enrollment: 10
Sex: ALL
Minimum age (years): 55
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients undergoing carotid endarterectomy

Brief summary: The build up of plaque in the wall of the artery supplying blood to the brain poses a risk of stroke when the plaques become unstable and fragile. It is important to determine which patients are most at risk so that surgery can be performed. There is evidence that the risk is greatest when these plaques become oxygen deficient (hypoxic). The investigators wish to use PET imaging to identify hypoxic plaque, to help decide whether and when to perform surgery. The investigators have developed radiotracers (imaging agents) for this purpose, and this study is to determine whether they will work in patients.


Eligibility criteria: Inclusion Criteria:

* Male/Female patients who are 55yrs or older and for whom carotid endarterectomy is clinically indicated and a decision has been made to perform a carotid endarterectomy.
* Normal liver and adequate renal function. Assessed by measuring eGFR (\>50ml/min) and creatinine (\<130μmol/L)
* Life expectancy \> 12 weeks
* Patients should be able to tolerate head/neck mask as well as lying in the PET-CT scanner

Exclusion Criteria:

* Abnormal liver and renal function (eGFR \<50ml/min, Creatinine \>130μmol/L)
* Patient unwilling to provide written informed consent

Primary outcomes:
measure: Uptake of CuATSM in carotid plaque
timeFrame: Within 30 days of carotid endarterectomy
Secondary outcomes:
measure: Relationship of CuATSM uptake to plaque histology
timeFrame: Within 30 days of carotid endarterectomy
Other outcomes:
Locations:
city: London
country: United Kingdom
facility: St Thomas' Hospital
Study officials:
affiliation: King's College London
name: Matt Waltham, MA PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03817281: Collective Accuryn Physiologic Signals and Signatures
Official title: Collective Accuryn Physiologic Signals and Signatures: A Retrospective and Prospective Analysis (CAPSS Study)
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Critical Illness
Acute Kidney Injury
Sepsis
Septic Shock
Abdominal Compartment Syndrome
Lead sponsor: Potrero Medical
Sponsor class: INDUSTRY
First posted: 2019-01-25
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population will comprise patients from high acuity centers such as burn, trauma, surgical, and critical care units.

Brief summary: The CAPSS Study is a retrospective and prospective, multi-center, single-arm post-market data collection study with an FDA cleared device. Physiologic data measurements will be collected from enrolled subjects using electronic health records and data streams via the Accuryn Monitoring System. Analysis of these data has the potential to be able to acutely guide resuscitation and monitor trends for emerging critical conditions.

Detailed description: The primary objective of the CAPSS Study is to track and analyze changes in physiologic data streams to identify clinical signatures that may enable earlier diagnosis of, and effective intervention in, critical conditions.

Eligibility criteria: Inclusion Criteria:

1. Received Accuryn Monitoring System during hospital stay.
2. Diagnosed with or developed one or more of the targeted conditions while connected to the Accuryn Monitoring System.

Exclusion Criteria:

1. In the opinion of the investigator, the patient is unsuitable for the study.

Primary outcomes:
measure: Physiologic Changes
timeFrame: 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington Harborview Medical Center
state: Washington
Study officials:
affiliation: University of Washington Harborview
name: Eileen M Bulger, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02115581: Coenzyme Q10 Supplementation in Children With Idiopathic Dilated Cardiomyopathy
Official title: Effect of Coenzyme Q10 (Ubiquinone) Supplementation on Ventricular Function of Children With Idiopathic Dilated Cardiomyopathy.A Randomised Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Dilated Cardiomyopathy
Keywords: Coenzyme O10
Children
Idiopathic Dilated Cardiomyopathy
Lead sponsor: University of Tehran
Sponsor class: OTHER
First posted: 2014-04-16
Enrollment: 38
Sex: ALL
Minimum age (years): 6
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy.

Detailed description: This study aims to determine the effect of Coenzyme Q10 supplementation on conventional therapy of children with heart failure due to idiopathic dilated cardiomyopathy. In a prospective, randomized, double-blinded, placebo-controlled trial, patients younger than 18 years with idiopathic dilated cardiomyopathy randomizes to receive either Coenzyme Q10 or placebo. Echocardiographic systolic and diastolic function parameters are determined for every patient at baseline, after three,six and nine months of supplementation.

Eligibility criteria: Inclusion Criteria:

* Known cases of Idiopathic Dilated Cardiomyopathy (IDC)
* Those patients in whom heart failure medications were stable for at least 1 month
* More than 6 months aged

Exclusion Criteria:

* Recent modification in medications
* Hemodynamic instability
* Congenital heart disease
* Metabolic heart disease
* Cardiac dysfunction resulting from abnormalities in other organs and those with an acquired cardiomyopathy

Primary outcomes:
measure: Improvement in Left Ventricular Ejection Fraction
timeFrame: 6 months
measure: Improvement in Left Ventricular Filling Abnormality
timeFrame: 6 months
Secondary outcomes:
measure: Adverse Events
timeFrame: 6 months
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Children's Medical Center
Study officials:
affiliation: Children's Medical Center
name: Reza Shabanian, MD
role: STUDY_DIRECTOR
affiliation: Children's Medical Center
name: Armen Kocharian, MD
role: STUDY_CHAIR
affiliation: Children's Medical Center
name: Giv Heidari-Bateni, MD/MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00806481: Effects of Phosphate Binding With Sevelamer in Stage 3 Chronic Kidney Disease
Official title: Does Phosphate Binding With Sevelamer Carbonate Improve Cardiovascular Structure and Function in Patients With Early Chronic Kidney Disease?
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Kidney Failure, Chronic
Cardiovascular Diseases
Keywords: Phosphate
Lead sponsor: University Hospital Birmingham NHS Foundation Trust
Sponsor class: OTHER
Collaborators: name: Genzyme, a Sanofi Company
First posted: 2008-12-10
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: The purpose of this study is to determine whether lowering phosphate in patients with early chronic kidney disease with the phosphate binder sevelamer has beneficial effects on cardiovascular structure and function.


Eligibility criteria: Inclusion Criteria:

* Chronic kidney disease patients aged 18 to 80 years
* Chronic kidney disease stage 3 (defined as a glomerular filtration rate of 30-60 ml/min/1.73m2)
* Office blood pressure controlled to less than 140/90 mmHg for 12 months before entry into the study
* Total cholesterol less than 5.5 mmol/l

Exclusion Criteria:

* Existing or previous treatment within 1 year with a phosphate binder or vitamin D analogue
* Uncontrolled hyperphosphataemia (serum phosphate \>1.8 mmol/l)
* Uncontrolled secondary hyperparathyroidism (PTH \>80 pg/ml)
* Diabetes mellitus
* Pregnancy
* Moderate-severe cardiac valvular disease

Primary outcomes:
measure: Change in left ventricular mass
timeFrame: 36 weeks
Secondary outcomes:
measure: Aortic compliance as measured by cardiac magnetic resonance imaging
timeFrame: 36 weeks
measure: Arterial stiffness as measured by pulse wave velocity and pulse wave analysis
timeFrame: 36 weeks
measure: Arterial elastance as measured by echocardiography
timeFrame: 36 weeks
measure: Left ventricular systolic and diastolic elastance measured by echocardiography
timeFrame: 36 weeks
measure: Bone density on dual-energy x-ray absorptiometry scanning
timeFrame: 36 weeks
Other outcomes:
Locations:
city: Birmingham
country: United Kingdom
facility: University Hospital Birmingham NHS Foundation Trust
state: West Midlands
Study officials:
affiliation: University Hospital Birmingham NHS Foundation Trust
name: Charles J Ferro, BSc (Hons), MBChB, FRCP, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Chue CD, Townend JN, Steeds RP, Ferro CJ. Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial. Trials. 2011 Feb 2;12:30. doi: 10.1186/1745-6215-12-30.
Clinical trial NCT05093881: Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Official title: Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Alcoholic Cirrhosis
Lead sponsor: Pharmicell Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2021-10-26
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: This Long-term follow-up is designed to evaluate the safety of patient with Alcoholic Liver Cirrhosis who had administered Cellgram-LC in PMC-P-07 study.

Detailed description: To evaluate the safety for 60 months after a single dose of Cellgram-LC in patients with alcoholic liver cirrhosis.

Eligibility criteria: Inclusion Criteria:

1. Those who participated in PMC-P-07 clinical trials and received Cellgram-LC
2. Those who voluntarily agreed in writing to participate in this investigation

Exclusion Criteria:

-

Primary outcomes:
measure: Rate of AESI
timeFrame: For 5 years
measure: Rate of Liver transplant
timeFrame: For 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Bucheon
country: Korea, Republic of
facility: Soonchunhyang University Hospital
city: Cheonan
country: Korea, Republic of
facility: Soonchunhyang University Hospital
city: ChunCheon
country: Korea, Republic of
facility: Gangwon National University Hospital
city: ChunCheon
country: Korea, Republic of
facility: Hallym Univ. Medical Center
city: Gangneung-si
country: Korea, Republic of
facility: Gangneung Asan Hospital
city: Seoul
country: Korea, Republic of
facility: Eunpyeong St. Mary's Hospital
city: Seoul
country: Korea, Republic of
facility: Korea University Anam Hospital
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
city: Seoul
country: Korea, Republic of
facility: Soonchunhyang University Hospital
city: Wonju
country: Korea, Republic of
facility: Wonju Severance Christian Hospital
city: Yongin
country: Korea, Republic of
facility: Yongin Severance Hospital
Study officials:
affiliation: Wonju Severance Christian Hospital
name: Moonyoung Kim
role: PRINCIPAL_INVESTIGATOR
References: